Synergy Pharmaceuticals Inc (SGYP.O) Key Developments | Reuters.com
Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

3.80USD
30 Jun 2016
Change (% chg)

-- (--)
Prev Close
$3.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,737,930
52-wk High
$10.15
52-wk Low
$2.50

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals reports Q1 loss per share $0.51
Tuesday, 10 May 2016 04:30pm EDT 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals reports first quarter 2016 financial results and business update . Q1 loss per share $0.51 .Q1 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S.  Full Article

Synergy Pharmaceuticals Inc announces $89.8 million registered direct offering of common stock
Thursday, 5 May 2016 08:00am EDT 

Synergy Pharmaceuticals Inc:Entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.Offering is expected to close on or about May 6, 2016.Intends to use net proceeds to fund its commercialization activities for plecanatide, further clinical development of plecanatide and dolcanatide and for working capital and other general corporate purposes.  Full Article

Synergy Pharmaceuticals Inc files new drug application for plecanatide in chronic idiopathic constipation
Friday, 29 Jan 2016 11:57am EST 

Synergy Pharmaceuticals Inc:Files new drug application for plecanatide in chronic idiopathic constipation.Says if approved, Synergy plans to launch plecanatide with the cic indication in the first quarter of 2017.Plecanatide nda for cic is supported by positive results from two phase 3 clinical trials which Synergy completed in 2015.  Full Article

Synergy Pharmaceuticals Inc announces positive trial results with dolcanatide in patients with ulcerative colitis
Monday, 11 Jan 2016 06:00am EST 

Synergy Pharmaceuticals Inc:Announces positive trial results with dolcanatide in patients with ulcerative colitis, confirming the role of uroguanylin in inflammatory bowel disease.Says dolcanatide was also safe and well tolerated.Says analysis of the data indicates clear signals of improvement in dolcanatide-treated patients.  Full Article

Synergy Pharmaceuticals announces positive results in the second phase 3 trial of plecanatide in patients with chronic idiopathic constipation
Thursday, 30 Jul 2015 06:00am EDT 

Synergy Pharmaceuticals Inc:Announces positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in 1337 adult patients with chronic idiopathic constipation (CIC).  Full Article

Synergy Pharmaceuticals Inc initiates second phase 3 clinical trial of plecanatide
Tuesday, 23 Jun 2015 06:00am EDT 

Synergy Pharmaceuticals Inc:Says initiation of second of two pivotal phase 3 clinical trials evaluating efficacy and safety of two different plecanatide treatment doses (3.0 mg and 6.0 mg), taken as a tablet once-a-day, in patients with irritable bowel syndrome with constipation (IBS-C).Says phase 3 IBS-C program includes two randomized, 12-week, double-blind, placebo-controlled pivotal trials conducted in the United States and each trial is expected to enroll about 1050 adult patients with IBS-C.Primary efficacy endpoint for both trials is the percentage of patients who are Overall Responders during the 12 week treatment period.Says an Overall Responder, as defined by the FDA, is a patient who is a weekly responder for at least 6 of the 12 treatment weeks.  Full Article

Synergy Pharmaceuticals announces positive results in the first phase 3 trial of plecanatide in patients with chronic idiopathic constipation
Wednesday, 17 Jun 2015 06:00am EDT 

Synergy Pharmaceuticals Inc:Announces positive results in the first phase 3 trial of plecanatide in patients with chronic idiopathic constipation (cic).Says 15 patients in the trial (1.1 pct.) experienced serious adverse events.Data indicates that both plecanatide 3.0 mg and 6.0 mg doses met the study's primary endpoint.Plans to file its first new drug application (NDA) with plecanatide in the cic indication in the fourth quarter of this year.Says plans to announce top-line data results from the second phase 3 cic trial with plecanatide in the first half of Q3 2015.Plecanatide 3.0 mg and 6.0 mg showed statistical significance in proportion of patients in the intention-to-treat population.  Full Article

Synergy Pharmaceuticals Inc initiates first phase 3 clinical trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
Thursday, 18 Dec 2014 06:00am EST 

Synergy Pharmaceuticals Inc:Announced the initiation of the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, for the treatment of irritable bowel syndrome with constipation (IBS-C).Says it is also evaluating 3.0 and 6.0 mg doses of plecanatide in two ongoing pivotal phase 3 trials for chronic idiopathic constipation (CIC), scheduled to read out top-line results in Q2 and Q3 2015.Says the primary efficacy endpoint for this trial is the percentage of patients who are Overall Responders during the 12 week treatment period.Says it plans to initiate the second pivotal phase 3 IBS-C trial with plecanatide in the H1 2015.  Full Article

Synergy Pharmaceuticals announces positive results of SP-333 Phase 2 Trial in patients with opioid-induced constipation
Wednesday, 19 Nov 2014 08:00am EST 

Synergy Pharmaceuticals Inc:Says positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0, and 6.0 mg) compared with placebo in 289 patients with opioid-induced constipation.SP-333 was safe and well tolerated at all doses.  Full Article

Synergy Pharmaceuticals Inc announces issuance of $200 mln of 7.50 pct convertible senior notes
Monday, 3 Nov 2014 04:01pm EST 

Synergy Pharmaceuticals Inc:Announced the closing of its previously announced private offering of $200 million aggregate principal amount of 7.50 pct Convertible Senior Notes due 2019.Notes are unsecured, senior obligations of Synergy and bear interest at a rate of 7.50 pct per year, payable semiannually in arrears on May 1 and Nov. 1 of each year, beginning on May 1, 2015.Notes will mature on Nov. 1, 2019, unless earlier purchased or converted.Intends to use the net proceeds from this offering primarily to fund the ongoing clinical development of plecanatide and any remaining proceeds will be used for working capital and other general corporate purposes.  Full Article

BRIEF-Synergy Pharmaceuticals reports Q1 loss per share $0.51

* Synergy Pharmaceuticals reports first quarter 2016 financial results and business update